Overall, our results demonstrate that EMT of HER2-positive breast cancer cells causes the emergence of a subpopulation of mesenchymal-like cells which are HER2-low/negative and highly resistant to trastuzumab and lapatinib. This evidence concerns the gene ERBB2 and breast carcinoma.